# Bio-Rad Narrows 2026 Operating Margin Target to Upper Half of Range By John Kim Canonical URL: https://www.tokenpost.com/news/business/49990 Published: 2026-11-06T09:34:40.000Z Updated: 2026-11-06T09:34:40.000Z Section: Business > The company maintained its non-GAAP gross-margin range of 53% to 54% and kept its currency-neutral revenue outlook. Bio-Rad Laboratories, Inc. now expects its 2026 non-GAAP operating margin to be in the upper half of a 10% to 12% range, sharpening its target after third-quarter sales edged higher. The narrower expectation follows [third-quarter results]() that retained the full operating margin range. Bio-Rad maintained its non-GAAP gross-margin range of 53% to 54%. Its non-GAAP currency-neutral revenue outlook remains a decline of about 3% to growth of about 0.5% for the year. Bio-Rad kept its free cash flow estimate at about $290 million to $340 million. The narrower operating-margin target remains within the original 10% to 12% range. Bio-Rad generated $656.4 million in third-quarter sales, 0.5% more than a year earlier. Clinical Diagnostics revenue rose 2.7% to $401.8 million, while Life Science revenue fell 2.8% to $254.6 million. ## Links in this article - [third-quarter results](https://www.tokenpost.com/news/business/49605)